Gil Labrucherie Insider Trading for 4,941 Shares of Nektar Therapeutics (NKTR); Shorts at HEMPAMERICANA (HMPQ) Raised By 489.81%

HempAmericana, Inc (OTCMKTS:HMPQ) Logo

HEMPAMERICANA INC (OTCMKTS:HMPQ) had an increase of 489.81% in short interest. HMPQ’s SI was 434,100 shares in May as released by FINRA. Its up 489.81% from 73,600 shares previously. The stock decreased 1.81% or $0.0003 during the last trading session, reaching $0.0152. About 13.81M shares traded. HempAmericana, Inc (OTCMKTS:HMPQ) has 0.00% since May 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Today, the SVP & Chief Financial Officer of Nektar Therapeutics, Mr. Gil Labrucherie, sold a substantial amount of company shares – 4,941, amounting to $412,030 U.S. Dollars, which is calculated based on a stock price of $83.4 for share. In the last month, he also sold 94,941 shares that are worth $7,976,230 USD. This sell was pretty big one, so clearly it won’t go a secret. Presently, he has ownership of 94,798 shares or roughly 0.06% of Nektar Therapeutics’s market cap. Published 18-05-2018, you can find out more about the trade by accessing the following public report here.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on August, 14. They expect $0.27 EPS, up 169.23% or $0.66 from last year’s $-0.39 per share. NKTR’s profit will be $46.28M for 78.98 P/E if the $0.27 EPS becomes a reality. After $-0.60 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -145.00% EPS growth.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” on May 16, 2018, also Fool.com with their article: “Here’s Why Nektar Therapeutics Fell as Much as 11.1% Today” published on May 17, 2018, Nasdaq.com published: “Why Dell Technologies, Nektar Therapeutics, and Westport Fuel Systems Jumped Today” on May 18, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Nasdaq.com and their article: “Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)” published on May 18, 2018 as well as Nasdaq.com‘s news article titled: “3 Stocks to Watch on Friday: Alphabet Inc (GOOG, GOOGL), Nektar Therapeutics (NKTR) and Solaredge Technologies ..” with publication date: May 11, 2018.

The stock increased 7.66% or $6.07 during the last trading session, reaching $85.3. About 3.34M shares traded or 13.24% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 20, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $79.50’s average target is -6.80% below currents $85.3 stock price. Nektar Therapeutics had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Monday, June 5 by Aegis Capital. The firm has “Buy” rating given on Tuesday, November 8 by Aegis Capital. Jefferies maintained it with “Buy” rating and $23.0 target in Wednesday, October 18 report. H.C. Wainwright reinitiated the stock with “Buy” rating in Monday, April 2 report. On Friday, April 13 the stock rating was maintained by PiperJaffray with “Overweight”. The firm earned “Buy” rating on Tuesday, July 18 by J.P. Morgan. The firm earned “Buy” rating on Monday, April 9 by Cowen & Co. The stock has “Buy” rating by Roth Capital on Wednesday, August 30. Mizuho maintained the shares of NKTR in report on Friday, April 6 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Monday, September 21.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $14.62 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Investors sentiment decreased to 1.19 in Q4 2017. Its down 0.21, from 1.4 in 2017Q3. It dropped, as 18 investors sold Nektar Therapeutics shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Credit Suisse Ag holds 0.02% or 337,785 shares. Granahan Mgmt Ma owns 0.74% invested in Nektar Therapeutics (NASDAQ:NKTR) for 156,517 shares. Stifel Fincl reported 0% in Nektar Therapeutics (NASDAQ:NKTR). Td Asset accumulated 0% or 22,800 shares. Bnp Paribas Arbitrage accumulated 92,307 shares. Opaleye Mgmt Incorporated stated it has 1.53% in Nektar Therapeutics (NASDAQ:NKTR). Riverhead Mgmt Limited Liability Corporation invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR). 263,506 are owned by Alliancebernstein Limited Partnership. Us Commercial Bank De stated it has 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Camber Ltd Liability Company has invested 9.79% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Great West Life Assurance Can invested 0.03% in Nektar Therapeutics (NASDAQ:NKTR). Profund Advisors Ltd Company holds 0.19% or 80,937 shares. Proshare Ltd invested in 0.05% or 115,875 shares. Sabby Mngmt Lc, New Jersey-based fund reported 20,000 shares. Kennedy Cap Mngmt invested in 280,868 shares or 0.3% of the stock.

Since December 13, 2017, it had 0 insider purchases, and 21 selling transactions for $88.95 million activity. 12,788 shares were sold by ROBIN HOWARD W, worth $1.06M. Shares for $2.07 million were sold by CHESS ROBERT on Thursday, May 3. Shares for $1.76 million were sold by KUEBLER CHRISTOPHER A. 220,144 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $21.85M were sold by Nicholson John. Doberstein Stephen K also sold $201,212 worth of Nektar Therapeutics (NASDAQ:NKTR) shares. Shares for $53,046 were sold by Hora Maninder. The insider Thomsen Jillian B. sold $1.41M.

HempAmericana, Inc. researches, develops, and sells products made of industrial hemp in the United States. The company has market cap of $26.23 million. It provides hemp concrete, hemp bags, hemp seeds for consumption, hemp clothing, and hemp rolling paper products. It currently has negative earnings.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart